By Nigam Arora & Dr. Natasha Arora
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
Very Nice Profits
The power of buy zones is on display. Pharmaceutical company Eli Lilly (LLY) stock fell in the buy zone for aggressive investors not that long ago. The average buy price is $318.45. It has quickly moved to $435.79 as of this writing.
Drivers
There are two drugs driving Eli Lilly stock higher:
- Investors are excited, anticipating mega blockbuster drug Mounjaro. Mounjaro is currently approved for Type 2 Diabetes and could be FDA approved for weight loss as early as the end of the year.
- Eli Lilly stock took another leg up on strong clinical trial results for its Alzheimer’s drug donanemab. In a phase III clinical trial, donanemab slowed cognitive decline by 35% and halted early progression of the disease in half of the trial participants.
Bad News
There are safety concerns with donanemab. Two trial participants had fatal brain swelling.
Approval
Eli Lilly is proceeding with a submission to the FDA for Alzheimer’s drug donanemab. If approved, donanemab will be the third Alzheimer’s drug on the market.
Pipeline and Portfolio
Eli Lilly has a strong drug pipeline and a competitive portfolio.
Target Zone
LLY stock can easily run much higher. The new target zone is 🔒 (To see the locked content, please take a 30 day free trial).
Buy Zone
The ideal buy zone is 🔒, but LLY may not fall that low. For more aggressive investors, the buy zone is 🔒. The maximum recommended quantity is 🔒.
Stop Zone
The mental stop zone is 🔒.
What To Do Now
Even though the long term target is being raised, in the short term, the stock can easily pull back. Since there are substantial profits, it is simply prudent to book partial profits in the zone of 🔒.
Those not in the stock may consider following the parameters given above.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
